Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and early outcome

	Infused (n = 67)	Noninfused (n = 13)	P value
Characteristics
Age, median (range), y	44 (22-69)	58 (32-70)	.014
ECOG-PS, n (%)
0	17/67 (30.4)	2/13 (15.4)	.42∗
1	31/67 (55.4)	8/13 (61.5)
2+	8/67 (14.2)	3/13 (23.1)
Baseline
CNS involvement	7/67 (10.4)	0/13 (0)	.59
Ph⁺ ALL	20/67 (29.9)	2/13 (15.4)	.33
Prior lines, n (%)
1	5/67 (7.5)	3/13 (23.1)	.55†
2	27/67 (40.3)	5/13 (38.5)
3+	35/67 (52.2)	5/13 (38.5)
Prior therapy, n (%)
Allo-HSCT	47/67 (70.2)	4/13 (30.8)	.011
Inotuzumab	12/67 (17.9)	4/13 (30.8)	.28
BLIN	42/67 (62.7)	9/13 (69.2)	.76
Before CAR T cell
CNS involvement	10/67 (14.9)	N/A
BM blasts ≥25%	14/64 (22)	N/A
Safety and early outcome
CRS, n (%); grade 3+	54/67 (80.6); 4/54 (7.4)	N/A
ICANS, n (%); grade 3+	32/67 (47.8); 6/32 (18.8)	N/A
CR	52/67 (77.6)	N/A
MRD-negative CR	41/52 (78.8)	N/A

	Infused (n = 67)	Noninfused (n = 13)	P value
Characteristics
Age, median (range), y	44 (22-69)	58 (32-70)	.014
ECOG-PS, n (%)
0	17/67 (30.4)	2/13 (15.4)	.42∗
1	31/67 (55.4)	8/13 (61.5)
2+	8/67 (14.2)	3/13 (23.1)
Baseline
CNS involvement	7/67 (10.4)	0/13 (0)	.59
Ph⁺ ALL	20/67 (29.9)	2/13 (15.4)	.33
Prior lines, n (%)
1	5/67 (7.5)	3/13 (23.1)	.55†
2	27/67 (40.3)	5/13 (38.5)
3+	35/67 (52.2)	5/13 (38.5)
Prior therapy, n (%)
Allo-HSCT	47/67 (70.2)	4/13 (30.8)	.011
Inotuzumab	12/67 (17.9)	4/13 (30.8)	.28
BLIN	42/67 (62.7)	9/13 (69.2)	.76
Before CAR T cell
CNS involvement	10/67 (14.9)	N/A
BM blasts ≥25%	14/64 (22)	N/A
Safety and early outcome
CRS, n (%); grade 3+	54/67 (80.6); 4/54 (7.4)	N/A
ICANS, n (%); grade 3+	32/67 (47.8); 6/32 (18.8)	N/A
CR	52/67 (77.6)	N/A
MRD-negative CR	41/52 (78.8)	N/A

ECOG-PS, Eastern Cooperative Oncology Group performance status; MRD, minimal residual disease; N/A, nonapplicable; Ph, Philadelphia chromosome.

ECOG 0/1 vs 2+.

1/2 lines vs 3+.